{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:35:53Z","timestamp":1785522953716,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05645-7","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:56:44Z","timestamp":1785135404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cycloastragenol overcomes trastuzumab resistance in HER2-positive breast cancer by regulating cell cycle and epithelial-mesenchymal transition through EZH2\/PTEN\/AKT pathway"],"prefix":"10.1007","author":[{"given":"Mingyuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenggang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoshuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"5645_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/11782234241285411","volume":"18","author":"S Abdel-Ghany","year":"2024","unstructured":"Abdel-Ghany S, Khalid Y, Mohamed S, Mohamed G, Mohdy E, Ezzat A, Madian EF, Said OA, Abdel-Hakeem MA, Nazih M, Khoder A, Sabit H (2024) Trastuzumab induces apoptosis and cell cycle arrest in triple-negative breast cancer, suggesting repurposing potential. Breast Cancer (Auckl) 18:11782234241285411","journal-title":"Breast Cancer (Auckl)"},{"key":"5645_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155550","volume":"262","author":"S Ahuja","year":"2024","unstructured":"Ahuja S, Khan AA, Zaheer S (2024) Understanding the spectrum of HER2 status in breast cancer: from HER2-positive to ultra-low HER2. Pathol Res Pract 262:155550","journal-title":"Pathol Res Pract"},{"key":"5645_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s11864-024-01277-2","volume":"25","author":"ARM Avelino","year":"2024","unstructured":"Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV (2024) Updates in treatment of HER2-positive metastatic breast cancer. Curr Treat Options Oncol 25:1471\u20131481","journal-title":"Curr Treat Options Oncol"},{"key":"5645_CR4","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1038\/s41418-021-00799-8","volume":"28","author":"C Bassi","year":"2021","unstructured":"Bassi C, Fortin J, Snow BE, Wakeham A, Ho J, Haight J, You-Ten A, Cianci E, Buckler L, Gorrini C, Stambolic V, Mak TW (2021) The PTEN and ATM axis controls the G1\/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer. Cell Death Differ 28:3036\u20133051","journal-title":"Cell Death Differ"},{"key":"5645_CR5","doi-asserted-by":"publisher","first-page":"8640","DOI":"10.3390\/ijms25168640","volume":"25","author":"AB Boz Er","year":"2024","unstructured":"Boz Er AB, Er I (2024) Targeting ITG\u03b23 to overcome trastuzumab resistance through epithelial-mesenchymal transition regulation in HER2-positive breast cancer. Int J Mol Sci 25:8640","journal-title":"Int J Mol Sci"},{"key":"5645_CR6","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/1759-7714.14474","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y, Wang L, Pang S, Li Y, Zou B, Zhou G, Gu J (2022) Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thoracic Cancer 13:1961\u20131973","journal-title":"Thoracic Cancer"},{"key":"5645_CR7","first-page":"2642","volume":"17","author":"S Chen","year":"2018","unstructured":"Chen S, Yao F, Xiao Q, Liu Q, Yang Y, Li X, Jiang G, Kuno T, Fang Y (2018) EZH2 inhibition sensitizes tamoxifen-resistant breast cancer cells through cell cycle regulation. Mol Med Rep 17:2642\u20132650","journal-title":"Mol Med Rep"},{"key":"5645_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4048\/jbc.2021.24.e33","volume":"24","author":"JH Cheun","year":"2021","unstructured":"Cheun JH, Won J, Jung JG, Kim HK, Han W, Lee HB (2021) Impact of trastuzumab on ipsilateral breast tumor recurrence for human epidermal growth factor receptor 2-positive breast cancer after breast-conserving surgery. J Breast Cancer 24:301\u2013314","journal-title":"J Breast Cancer"},{"key":"5645_CR9","doi-asserted-by":"crossref","unstructured":"Debnath P, Huirem RS, Dutta P, Palchaudhuri S (2022) Epithelial-mesenchymal transition and its transcription factors. Biosci Rep 42:BSR20211754","DOI":"10.1042\/BSR20211754"},{"key":"5645_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s11864-023-01108-w","volume":"24","author":"N Dempsey","year":"2023","unstructured":"Dempsey N, Sandoval A, Mahtani R (2023) Metastatic HER2-positive breast cancer: is there an optimal sequence of therapy? Curr Treat Options Oncol 24:1120\u20131137","journal-title":"Curr Treat Options Oncol"},{"key":"5645_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004874","volume":"10","author":"G Deng","year":"2022","unstructured":"Deng G, Zhou L, Wang B, Sun X, Zhang Q, Chen H, Wan N, Ye H, Wu X, Sun D, Sun Y, Cheng H (2022) Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation. J Immunother Cancer 10:e004874","journal-title":"J Immunother Cancer"},{"issue":"1","key":"5645_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W (2020) EZH2: a novel target for cancer treatment. J Hematol Oncol 13:104","journal-title":"J Hematol Oncol"},{"key":"5645_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12282-022-01425-2","volume":"30","author":"M Futamura","year":"2023","unstructured":"Futamura M, Ishihara K, Nagao Y, Ogiso A, Niwa Y, Nakada T, Kawaguchi Y, Ikawa A, Kumazawa I, Mori R, Kitazawa M, Hosono Y, Kuno M, Kawajiri M, Nakakami A, Takeuchi M, Morikawa A, Tokumaru Y, Katagiri Y, Asano Y, Mushika Y, Shimokawa T, Matsuhasih N (2023) Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast Cancer 30:293\u2013301","journal-title":"Breast Cancer"},{"key":"5645_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel S, Bergholz JS, Zhao JJ (2022) Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer 22:356\u2013372","journal-title":"Nat Rev Cancer"},{"key":"5645_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166431","volume":"1868","author":"R Gundamaraju","year":"2022","unstructured":"Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, Chattopadhyay I, Rao PV, Ghavami S (2022) Autophagy and EMT in cancer and metastasis: who controls whom? Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease 1868:166431","journal-title":"Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"5645_CR16","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s10528-025-11170-8","volume":"64","author":"Y Han","year":"2025","unstructured":"Han Y, Guo J, Yang T, Liu X, Yan H, Li Y, Yao J (2025) KDM3A modulates trastuzumab resistance in HER2-positive breast cancer cells via the PI3K\/AKT\/ERK pathway. Biochem Genet 64:3221\u20133233","journal-title":"Biochem Genet"},{"key":"5645_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2019.152907","volume":"59","author":"ST Hwang","year":"2019","unstructured":"Hwang ST, Kim C, Lee JH, Chinnathambi A, Alharbi SA, Shair OHM, Sethi G, Ahn KS (2019) Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. Phytomedicine 59:152907","journal-title":"Phytomedicine"},{"key":"5645_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4048\/jbc.2016.19.1.53","volume":"19","author":"SH Jang","year":"2016","unstructured":"Jang SH, Lee JE, Oh MH, Lee JH, Cho HD, Kim KJ, Kim SY, Han SW, Kim HJ, Bae SB, Lee HJ (2016) High EZH2 protein expression is associated with poor overall survival in patients with luminal A breast cancer. J Breast Cancer 19:53\u201360","journal-title":"J Breast Cancer"},{"key":"5645_CR19","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ (2020) Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer 126:4278\u201388","journal-title":"Cancer"},{"key":"5645_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104624","volume":"207","author":"X Li","year":"2025","unstructured":"Li X, Zhang X, Yin S, Nie J (2025) Challenges and prospects in HER2-positive breast cancer-targeted therapy. Crit Rev Oncol Hematol 207:104624","journal-title":"Crit Rev Oncol Hematol"},{"key":"5645_CR21","doi-asserted-by":"publisher","first-page":"28588","DOI":"10.1039\/C8RA05727C","volume":"8","author":"F Li","year":"2018","unstructured":"Li F, Zhang L, Feng F, Zheng K, Li Y, Wang T, Ren G (2018) Livin participates in resistance to trastuzumab therapy for breast cancer through ERK1\/2 and AKT pathways and promotes EMT-like phenotype. RSC Adv 8:28588\u201328601","journal-title":"RSC Adv"},{"key":"5645_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309988","volume":"11","author":"W Li","year":"2024","unstructured":"Li W, Huang M, Wu Z, Zhang Y, Cai Y, Su J, Xia J, Yang F, Xiao D, Yang W, Xu Y, Liu Z (2024) mRNA-lipid nanoparticle-mediated restoration of PTPN14 exhibits antitumor effects by overcoming anoikis resistance in triple-negative breast cancer. Adv Sci 11:e2309988","journal-title":"Adv Sci"},{"key":"5645_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang Q (2023) The roles of EZH2 in cancer and its inhibitors. Med Oncol 40:167","journal-title":"Med Oncol"},{"key":"5645_CR24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1080\/00498254.2016.1204568","volume":"47","author":"PK Ma","year":"2017","unstructured":"Ma PK, Wei BH, Cao YL, Miao Q, Chen N, Guo CE, Chen HY, Zhang YJ (2017) Pharmacokinetics, metabolism, and excretion of cycloastragenol, a potent telomerase activator in rats. Xenobiotica 47:526\u2013537","journal-title":"Xenobiotica"},{"key":"5645_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Pandiella A, Vargas-Castrill\u00f3n E, D\u00edaz-Rodr\u00edguez E, Iglesias-Hernang\u00f3mez T, Mart\u00ednez Cano C, Fern\u00e1ndez-Cuesta I, Winkow E, Perell\u00f3 MF (2024) Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol 198:104355","journal-title":"Crit Rev Oncol Hematol"},{"key":"5645_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijscr.2021.01.044","volume":"79","author":"M Matsumoto","year":"2021","unstructured":"Matsumoto M, Yano H, Otsubo R, Tanaka A, Nagayasu T (2021) Favorable survival with combined treatment in a metastatic breast cancer patient undergoing hemodialysis: a case report. Int J Surg Case Rep 79:206\u2013209","journal-title":"Int J Surg Case Rep"},{"key":"5645_CR27","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","volume":"9","author":"FI Montalto","year":"2020","unstructured":"Montalto FI, De Amicis F (2020) Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells 9:2648","journal-title":"Cells"},{"key":"5645_CR28","first-page":"868","volume":"11","author":"B Nami","year":"2021","unstructured":"Nami B, Ghanaeian A, Black C, Wang Z (2021) Epigenetic silencing of HER2 expression during epithelial-mesenchymal transition leads to trastuzumab resistance in breast cancer. Life (Basel) 11:868","journal-title":"Life (Basel)"},{"key":"5645_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.semcdb.2020.04.003","volume":"107","author":"N Palmer","year":"2020","unstructured":"Palmer N, Kaldis P (2020) Less-well known functions of cyclin\/CDK complexes. Semin Cell Dev Biol 107:54\u201362","journal-title":"Semin Cell Dev Biol"},{"key":"5645_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038508","volume":"103","author":"L Pan","year":"2024","unstructured":"Pan L, Li J, Xu Q, Gao Z, Yang M, Wu X, Li X (2024) HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review. Medicine (Baltimore) 103:e38508","journal-title":"Medicine (Baltimore)"},{"key":"5645_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01825-8","volume":"4","author":"K Pappas","year":"2021","unstructured":"Pappas K, Martin TC, Wolfe AL, Nguyen CB, Su T, Jin J, Hibshoosh H, Parsons R (2021) NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Commun Biol 4:312","journal-title":"Commun Biol"},{"key":"5645_CR32","doi-asserted-by":"publisher","first-page":"15213","DOI":"10.3390\/ijms232315213","volume":"23","author":"D Park","year":"2022","unstructured":"Park D, Jung JH, Ko HM, Jee W, Kim H, Jang HJ (2022) Antitumor effect of cycloastragenol in colon cancer cells via p53 activation. Int J Mol Sci 23:15213","journal-title":"Int J Mol Sci"},{"key":"5645_CR33","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.7150\/thno.93236","volume":"14","author":"M Park","year":"2024","unstructured":"Park M, Jung E, Park JM, Park S, Ko D, Seo J, Kim S, Nam KD, Kang YK, Farrand L, Hoang VH, Nguyen CT, La MT, Nam G, Park HJ, Ann J, Lee J, Kim YJ, Kim JY, Seo JH (2024) The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer. Theranostics 14:2442\u20132463","journal-title":"Theranostics"},{"key":"5645_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100993","volume":"71","author":"D Ravindran Menon","year":"2023","unstructured":"Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, Bordag N, Emran AA, Giam M, Denil S, Pavelka N, Tan AC, Sturm RA, Haass NK, Rancati G, Herlyn M, Magnes C, Eccles MR, Fujita M, Schaider H (2023) H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resistance Updates\u202f: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 71:100993","journal-title":"Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy"},{"key":"5645_CR35","first-page":"22","volume":"7","author":"K Saleh","year":"2024","unstructured":"Saleh K, Khoury R, Khalife N, Chahine C, Ibrahim R, Tikriti Z, Le Cesne A (2024) Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resistance (Alhambra, Calif) 7:22","journal-title":"Cancer Drug Resistance (Alhambra, Calif)"},{"key":"5645_CR36","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.3390\/cancers13112778","volume":"13","author":"M Sanz-\u00c1lvarez","year":"2021","unstructured":"Sanz-\u00c1lvarez M, Mart\u00edn-Aparicio E, Luque M, Zazo S, Mart\u00ednez-Useros J, Eroles P, Rovira A, Albanell J, Madoz-G\u00farpide J, Rojo F (2021) The novel oral mTORC1\/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models. Cancers (Basel) 13:2778","journal-title":"Cancers (Basel)"},{"key":"5645_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2021.103055","volume":"100","author":"M Shen","year":"2021","unstructured":"Shen M, Young A, Autexier C (2021) PCNA, a focus on replication stress and the alternative lengthening of telomeres pathway. DNA Repair (Amst) 100:103055","journal-title":"DNA Repair (Amst)"},{"key":"5645_CR38","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345","journal-title":"CA Cancer J Clin"},{"key":"5645_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126","journal-title":"Nat Rev Drug Discov"},{"key":"5645_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1616894","volume":"12","author":"Y Tao","year":"2025","unstructured":"Tao Y, Chang J, Zhu X, Han J, Wang X, Sheng Y, Sun Z, Liu F, Tao Y, Wu H, Yu C, Liu H, Fan F (2025) The research on cycloastragenol in the treatment of brain metastases from lung cancer: mechanistic exploration of radiotherapy sensitization and amelioration of brain injury. Front Med 12:1616894","journal-title":"Front Med"},{"key":"5645_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.62382\/jcbt.v2i2.59","volume":"2","author":"H Vajihe","year":"2025","unstructured":"Vajihe H, Leila S, Sadri F (2025) Exploring ferroptosis and epigenetic regulation in gynecological cancers: implications for treatment strategies. Journal of Cancer Biomoleculars and Therapeutics 2:37\u201354","journal-title":"Journal of Cancer Biomoleculars and Therapeutics"},{"key":"5645_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-3-031-70875-6_24","volume":"1464","author":"J Veeraraghavan","year":"2025","unstructured":"Veeraraghavan J, De Angelis C, Gutierrez C, Liao FT, Sabotta C, Rimawi MF, Osborne CK, Schiff R (2025) HER2-positive breast cancer treatment and resistance. Adv Exp Med Biol 1464:495\u2013525","journal-title":"Adv Exp Med Biol"},{"key":"5645_CR43","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41571-024-00939-2","volume":"21","author":"AG Waks","year":"2024","unstructured":"Waks AG, Mart\u00ednez-S\u00e1ez O, Tarantino P, Braso-Maristany F, Pascual T, Cort\u00e9s J, Tolaney SM, Prat A (2024) Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance. Nat Rev Clin Oncol 21:818\u2013832","journal-title":"Nat Rev Clin Oncol"},{"key":"5645_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang Q, Bode AM, Zhang T (2023) Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol 7:58","journal-title":"NPJ Precis Oncol"},{"key":"5645_CR45","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.3390\/ijms23105679","volume":"23","author":"YL Wang","year":"2022","unstructured":"Wang YL, Wu WR, Lin PL, Shen YC, Lin YZ, Li HW, Hsu KW, Wang SC (2022) The functions of PCNA in tumor stemness and invasion. Int J Mol Sci 23:5679","journal-title":"Int J Mol Sci"},{"key":"5645_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41417-024-00819-y","volume":"31","author":"C Wang","year":"2024","unstructured":"Wang C, Bai C, Zhang Z, Zhou H, Gao H, Wang S, Yuan Y (2024) UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: a potential biomarker to identify patients resistant to trastuzumab treatment. Cancer Gene Ther 31:1525\u20131535","journal-title":"Cancer Gene Ther"},{"key":"5645_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1006429","volume":"12","author":"ZH Wang","year":"2022","unstructured":"Wang ZH, Zheng ZQ, Jia SC, Liu SN, Xiao XF, Chen GY, Liang WQ, Lu XF (2022) Trastuzumab resistance in HER2-positive breast cancer: mechanisms, emerging biomarkers and targeting agents. Front Oncol 12:1006429","journal-title":"Front Oncol"},{"key":"5645_CR48","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ptr.6946","volume":"35","author":"J Wu","year":"2021","unstructured":"Wu J, Zeng Z, Li Y, Qin H, Zuo C, Zhou C, Xu D (2021) Cycloastragenol protects against glucocorticoid-induced osteogenic differentiation inhibition by activating telomerase. Phytother Res 35:2034\u20132044","journal-title":"Phytother Res"},{"key":"5645_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164428","author":"M Yang","year":"2023","unstructured":"Yang M, Li Y, Kong L, Huang S, He L, Liu P, Mo S, Lu X, Lin X, Xiao Y, Shi D, Huang X, Chen B, Chen X, Ouyang Y, Li J, Lin C, Song L (2023) Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI164428","journal-title":"J Clin Invest"},{"key":"5645_CR50","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","volume":"68","author":"LH Yang","year":"2021","unstructured":"Yang LH, Du P, Liu W, An LK, Li J, Zhu WY, Yuan S, Wang L, Zang L (2021) LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma 68:788\u2013797","journal-title":"Neoplasma"},{"key":"5645_CR51","first-page":"2175","volume":"16","author":"Y Yu","year":"2018","unstructured":"Yu Y, Zhou L, Yang Y, Liu Y (2018) Cycloastragenol: an exciting novel candidate for age-associated diseases. Exp Ther Med 16:2175\u20132182","journal-title":"Exp Ther Med"},{"key":"5645_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11450-9","volume":"23","author":"F Yu","year":"2023","unstructured":"Yu F, Li L, Zhang M, Sun S (2023) Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner. BMC Cancer 23:948","journal-title":"BMC Cancer"},{"key":"5645_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.62382\/jcbt.v3i1.87","volume":"3","author":"A Zabeti Touchaei","year":"2026","unstructured":"Zabeti Touchaei A (2026) The role of miR-21 in HER2-positive breast cancer: a comprehensive review of molecular mechanisms, biomarker potential, and therapeutic implications. Journal of Cancer Biomoleculars and Therapeutics 3:13\u201326","journal-title":"Journal of Cancer Biomoleculars and Therapeutics"},{"key":"5645_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217112","volume":"598","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhang L, He Y, Jiang D, Sun J, Luo Q, Liang H, Wang T, Li F, Tang Y, Yang Z, Liu W, Rao Y, Chen C (2024) PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. Cancer Lett 598:217112","journal-title":"Cancer Lett"},{"key":"5645_CR55","doi-asserted-by":"publisher","first-page":"31691","DOI":"10.1039\/C9RA05405G","volume":"9","author":"D Zhao","year":"2019","unstructured":"Zhao D, Li Y, Yu M (2019) LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN via EZH2. RSC Adv 9:31691\u201331698","journal-title":"RSC Adv"},{"key":"5645_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.joim.2024.05.004","volume":"22","author":"LH Zhu","year":"2024","unstructured":"Zhu LH, Liang YP, Yang L, Zhu F, Jia LJ, Li HG (2024) Cycloastragenol induces apoptosis and protective autophagy through AMPK\/ULK1\/mTOR axis in human non-small cell lung cancer cell lines. J Integr Med 22:503\u2013514","journal-title":"J Integr Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05645-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:21:12Z","timestamp":1785518472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":56,"alternative-id":["5645"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05645-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Ethics Committee of Shanghai Geriatric Medical Center (Approval No.: HZ-20240321).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript has neither been previously published nor is under consideration by any other journal. The authors have all approved the content of the paper.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}